The Claim
In adults with PPARG polymorphisms, supplementation with 2000 mg/day of omega-3 fatty acids for 90 days results in a significantly greater reduction in LDL cholesterol (11.7%) and triglycerides (12.8%) compared to adults without these polymorphisms, indicating a gene-supplement interaction that identifies a responsive subgroup.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People with a specific gene variation called PPARG may see much better results from taking omega-3 supplements—like lower bad cholesterol and triglycerides—than people without that gene variation.
See the scientific wording
The lipid-lowering effect of 2000 mg/day omega-3 fatty acids over 90 days is significantly greater in adults with PPARG polymorphisms than in those without, with a 11.7% greater reduction in LDL-C and 12.8% greater reduction in triglycerides, demonstrating a gene-supplement interaction that defines a responsive subgroup.
What the research says
1 studyPeople with a specific gene variation (PPARG) had much bigger drops in bad cholesterol and triglycerides when they took omega-3 pills, while others barely saw any change — so this gene tells us who will benefit most from omega-3s.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.